Production of mesenchymal stromal/stem cells according to good manufacturing practices: A review

Stem Cell Research and Therapy

Volumn 4, Issue 3, 2013, Pages

  Sensebé, Luc ^a,b   Gadelorge, Mélanie ^a,b   Fleury Cappellesso, Sandrine ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; CULTURE MEDIUM; MEMBRANE ANTIGEN;

BIOREACTOR; CELL ADHESION; CELL DIFFERENTIATION; CELL EXPANSION; CULTURE MEDIUM; DONOR SELECTION; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC STABILITY; GOOD MANUFACTURING PRACTICE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; REVIEW; SAFETY; STANDARDIZATION; CULTURE TECHNIQUE; CYTOLOGY; DONOR; HUMAN; METABOLISM; STANDARDS;

ANTIGENS, SURFACE; BIOREACTORS; CELL CULTURE TECHNIQUES; CULTURE MEDIA; HUMANS; MESENCHYMAL STROMAL CELLS; TISSUE DONORS;

EID: 84878847047     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt217     Document Type: Review

References (50)

1. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Friedenstein AJ, Gorskaja JF, Kulagina NN, Exp Hematol 1976 4 267 274 976387
2. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI, Bone Marrow Transplant 1995 16 557 564 8528172
3. The mesengenic process. Caplan AI, Clin Plast Surg 1994 21 429 435 7924141 (Pubitemid 24208964)
4. Repair of large bone defects with the use of autologous bone marrow stromal cells. Quarto R, Mastrogiacomo M, Cancedda R, Kupetov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M, N Engl J Med 2001 344 385 386 10.1056/NEJM200102013440516 11195802 (Pubitemid 32107654)
5. Role of the IFN-γ in the immunomodulatory activity of human mesenchymal stem cells. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F, Stem Cells 2005 24 386 398 16123384
6. Clinical-grade mesenchymal stromal cells produced under various GMP processes differ in their immunomodulatory properties: standardization of immune quality controls. Menard C, Pacelli L, Bassi G, Dulong J, Bifari F, Bezier I, Zanoncello J, Ricciardi M, Latour M, Bourin P, Schrezenmeier H, Sensebé L, Tarte K, Krampera M, Stem Cells Dev 2013 Jan 22 [Epub ahead of print]
7. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O, Lancet 2004 363 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
8. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C, JAMA 2012 307 1169 1177 10.1001/jama.2012.316 22436957
9. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Phinney DG, Prockop DJ, Stem Cells 2007 25 2896 2902 10.1634/stemcells.2007-0637 17901396 (Pubitemid 350127874)
10. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, Nishikawa SI, Cell 2007 129 1377 1388 10.1016/j.cell.2007.04.028 17604725 (Pubitemid 46970707)
11. A perivascular origin for mesenchymal stem cells in multiple human organs. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Bühring HJ, Giacobino JP, Lazzari L, Huard J, Peault B, Cell Stem Cell 2008 3 301 313 10.1016/j.stem.2008.07.003 18786417
12. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
13. Comparison of multilineage cells from human adipose tissue and bone marrow. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashijan P, Thomas B, Benhaim P, Chen I, Frazer J, Hedrick MH, Cells Tissues Organs 2003 174 101 109 10.1159/000071150 12835573 (Pubitemid 36819010)
14. Mesenchymal stromal cells: misconceptions and evolving concepts. Phinney DG, Sensebé L, Cytotherapy 2013 15 140 145 10.1016/j.jcyt.2012.11.005 23321325
15. Interactions between human mesenchymal stem cells and natural killer cells. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M, Stem Cells 2006 24 74 85 10.1634/stemcells.2004-0359 16099998
16. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebé L, Société Française de Greffe de Moelle et Thérapie Cellulaire, Blood 2010 115 1549 1553 10.1182/blood-2009-05-219907 20032501
17. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Gehron Robey P, Riminucci M, Bianco P, Cell 2007 131 324 336 10.1016/j.cell.2007.08.025 17956733 (Pubitemid 47592917)
18. Good manufacturing practices production of mesenchymal stem/stromal cells. Sensebe L, Bourin P, Tarte K, Hum Gene Ther 2011 22 19 26 10.1089/hum.2010.197 21028982
19. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I, Stem Cells 2004 22 675 682 10.1634/stemcells.22-5- 675 15342932 (Pubitemid 39172200)
20. Age-related changes in human bone marrow derived mesenchymal stem cells: consequences for cell therapies. Stolzing A, Jones E, McGonagle D, Scutt A, Mech Ageing Dev 2008 129 163 173 10.1016/j.mad.2007.12.002 18241911
21. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Bieback K, Kern S, Klüter H, Eichler H, Stem Cells 2004 22 625 634 10.1634/stemcells.22-4-625 15277708 (Pubitemid 39014578)
22. Molecular and cellular characterisation of highly purified stromal cells derived from human bone marrow. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons PJ, J Cell Sci 2003 116 1827 1835 10.1242/jcs.00369 12665563 (Pubitemid 36582169)
23. Human marrow stromal precursors are alpha 1 integrin subunit-positive. Deschaseaux F, Charbord P, J Cell Physiol 2000 184 319 325 10.1002/1097- 4652(200009)184:3<319::AID-JCP5>3.0.CO;2-N 10911362 (Pubitemid 30625494)
24. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Delorme B, Ringe J, Pontikoglou C, Gaillard J, Langonné A, Sensebé L, Noël D, Jorgensen C, Häupl T, Charbord P, Stem Cells 2009 27 1142 1151 10.1002/stem.34 19418444
25. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deluiliers GL, Exp Hematol 2002 30 783 791 10.1016/S0301-472X(02)00812-3 12135677 (Pubitemid 34835685)
26. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Colter DC, Sekiya I, Prockop DJ, Proc Natl Acad Sci U S A 2001 98 7841 7845 10.1073/pnas.141221698 11427725 (Pubitemid 32642648)
27. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ, Stem Cells 2002 20 530 541 10.1634/stemcells.20-6-530 12456961 (Pubitemid 35463066)
28. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R, Exp Hematol 2000 28 707 715 10.1016/S0301-472X(00)00160-0 10880757 (Pubitemid 30398528)
29. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ, J Cell Physiol 2005 205 228 236 10.1002/jcp.20391 15887229 (Pubitemid 41428905)
30. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Fekete N, Gadelorge M, Fürst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailänder V, Lotfi R, Ignatius A, Sensebé L, Bourin P, Schrezenmeier H, Rojewski MT, Cytotherapy 2012 14 540 554 10.3109/14653249.2012.655420 22296115
31. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. Fekete N, Rojewski MT, Fürst D, Kreja L, Ignatius A, Dausend J, Schrezenmeier H, PLoS One 2012 7 43255 10.1371/journal.pone.0043255 22905242
32. Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. Bouacida A, Rosset P, Trichet V, Guilloton F, Espagnolle N, Cordonier T, Heymann D, Layrolle P, Sensébé L, Deschaseaux F, PLoS One 2012 7 48648 10.1371/journal.pone.0048648 23144918
33. Effect of platelet-rich plasma on the in vitro proliferation and osteogenic differentiation of human mesenchymal stem cells on distinct calcium phosphate scaffolds: the specific surface area makes a difference. Kasten P, Vogel J, Beyen I, Weiss S, Niemeyer P, Leo A, Lüginbuhl R, J Biomater Appl 2008 23 169 188 10.1177/0885328207088269 18632770
34. A novel serum-free medium for the expansion of human mesenchymal stem cells. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC, Stem Cell Res Ther 2010 1 8 10.1186/scrt8 20504289
35. Design of bioreactors for mesenchymal stem cell tissue engineering. Godara P, McFarland CD, Nordon RE, J Chem Technol Biotechnol 2010 83 408 420 (Pubitemid 351460907)
36. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device Quantum Cell Expansion system. Rojewski MT, Fekete N, Baila S, Nguyen K, Fürst D, Antwiler D, Dausend J, Kreja L, Ignatius A, Sensebé L, Schrezenmeier H, Cell Transplant 2012 Oct 25 [Epub ahead of print]
37. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Estrada JC, Albo C, Benguira A, Dopazo A, Lopez-Romero P, Carrera-Quintanar L, Roche E, Clemente EP, Enriquez JA, Bernad A, Samper E, Cell Death Differ 2012 19 743 755 10.1038/cdd.2011.172 22139129
38. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their inflammatory properties. Bartosh TJ, Ylöstalo JH, Mohammadipoor A, Bazhanov N, Coble K, Claypool K, Lee RH, Choi H, Prockop DJ, Proc Natl Acad Sci U S A 2010 107 13724 13729 10.1073/pnas.1008117107 20643923
39. Ink4a/Arf expression is a biomarker of aging. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE, J Clin Invest 2004 114 1299 1307 15520862 (Pubitemid 40385301)
40. Cellular senescence: when bad things happen to good cells. Campisi J, d'Adda di Fagagna F, Nat Rev Mol Cell Biol 2007 8 729 740 17667954 (Pubitemid 47312822)
41. Adult human mesenchymal stem cell as a target for neoplastic transformation. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrødder H, Jensen T, Kassem M, Oncogene 2004 23 5095 5098 10.1038/sj.onc.1207651 15107831 (Pubitemid 38938744)
42. Replicative senescence of mesenchymal stem cells: a continuous and organized process. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD, PLoS One 2008 3 1 12
43. Spontaneous human adult stem cell transformation. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A, Cancer Res 2005 65 3035 3039 15833829 (Pubitemid 40524580)
44. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Røsland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lønning PE, Bjerkvig R, Schichor C, Cancer Res 2009 69 5331 5339 10.1158/0008-5472.CAN-08-4630 19509230
45. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Garcia S, Martin MC, de la Fuente R, Cigudosa JC, Garcia-Castro J, Bernad A, Exp Cell Res 2010 316 1648 1650 10.1016/j.yexcr.2010.02.016 20171963
46. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track. Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lønning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R, Cancer Res 2010 70 6393 6396 10.1158/0008-5472.CAN-10-1305 20631079
47. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F, Cancer Res 2007 67 9142 9149 10.1158/0008-5472.CAN-06-4690 17909019 (Pubitemid 47535900)
48. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Ben-David U, Mayshar Y, Benvenisty N, Cell Stem Cell 2011 9 97 102 10.1016/j.stem.2011.06.013 21816361
49. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Sensebé L, Tarte K, Galipeau J, Krampera M, Martin I, Phinney DG, Shi Y, Cell Stem Cell 2012 10 9 10 10.1016/j.stem.2011.12.005 22226349
50. Risk of tumorigenicity in mesenchymal stem cell-based therapies: bridging scientific observations and regulatory viewpoints. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Mačiulaitis R, Palomäki T, Schneider CK, Sensebé L, Tachdjian G, Tarte K, Tosca L, Salmikangas P, Cytotherapy 2013